A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (DELINOR)

Pfizer

Status

Completed

Conditions

Non-Small Cell Lung Cancer

Treatments

Drug: brigatinib

Drug: ceritinib

Drug: alectinib

Drug: afatinib

Drug: crizotinib

Drug: paclitaxel

Drug: nivolumab

Drug: osimertinib

Drug: entrectinib

Drug: carboplatin

Drug: atezolizumab

Drug: lorlatinib

Drug: erlotinib

Drug: gefitinib

Drug: docetaxel

Drug: dacomitinib

Drug: pembrolizumab

Drug: bevacizumab

Study type

Observational

Funder types

Industry

Identifiers

NCT05834348

DELINOR (Other Identifier)

B7461041

Details and patient eligibility

About

The main purpose of the study is to learn about the effectiveness and treatment sequence of lung cancer medicines. This study is performed outside of clinical trials in Norway in patients with metastatic non-small cell lung cancer. Non-small cell lung cancer is a group of lung cancers named for the kinds of cells found in the cancer and how the cells look under a microscope. Metastasis is when the cancer cells spread to other parts of the body.

This study includes patient's data from the database who:

Are 18 years of age or older.
Are confirmed to have metastatic non-small cell lung cancer between 01 January 2009 and 31 December 2022.

The study is based on data collection from 3 national health registries:

The Cancer Registry of Norway (CRN),
The Norwegian Patient Registry (NPR),
The Norwegian Drug Registry (NDR).

Data from these registries will be linked at an individual patient level to create a single, unified dataset. The information collected includes:

Diagnosis, cancer stage at diagnosis, date of diagnosis, birth year, type of medicinal treatment, date of treatment start and end, treating hospital, age, gender, etc.

Enrollment

5,279 patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients ≥ 18 years old with histologically confirmed stage IIIb, IIIc, IVa, or IVb NSCLC at the time of diagnosis
Received their first NSCLC diagnosis (stage IIIb, IIIc, IVa, or IVb) between 01 January 2009, and latest available year

Exclusion criteria

Patients ≥ 18 years old with histologically confirmed stage IIIb, IIIc, IVa, or IVb NSCLC at the time of diagnosis who received radiation therapy with curative intent, defined as a radiation dose larger than 50gy
If the data include patients diagnosed after 2021, IIIb patients will be excluded due to changes in the guideline. The updated guidelines for 2022 recommends that patients diagnosed with stage IIIb who have surgery with the intent to cure should not have ''curative'' radiation (i.e.: it is not possible to exclude these from the population from 2022).